Lead Claim Opportunity for Unicycive Investors Amid Securities Fraud Allegations

Unicycive Investors Urged to Join Class Action Lawsuit

The Rosen Law Firm, a prominent global player in investor rights, is reaching out to individuals who purchased securities of Unicycive Therapeutics, Inc. (NASDAQ: UNCY) during a specified time frame from December 29, 2025, to June 29, 2026. In light of recent developments indicating potential securities fraud, investors are reminded of a significant deadline: November 2, 2026. This date marks the cutoff for filing to become the lead plaintiff in the ongoing class action lawsuit against Unicycive.

Understanding the Class Action
Joining this class action offers a pathway for affected investors to seek compensation without the burden of upfront legal fees. Under a contingency fee arrangement, investors can potentially recover damages without incurring out-of-pocket costs. To learn how to participate, investors can visit Rosen Law Firm's dedicated page or contact Phillip Kim, Esq. via phone at 866-767-3653 or email at [email protected]

Background of the Case
The class action lawsuit against Unicycive Therapeutics stems from serious allegations. The complaint suggests that during the aforementioned class period, Unicycive and its representatives made false and misleading statements about their operational practices and the compliance status of their third-party manufacturing vendor. Key points of contention include:
1. Unicycive allegedly failed to inspect its manufacturing vendor's facilities, raising questions about compliance with good manufacturing practices.
2. The company reportedly lacked a reasonable basis to assert that its vendor had adequately addressed deficiencies pointed out by the U.S. Food and Drug Administration (FDA).
3. There seems to be an undisclosed risk that the FDA might seek additional information regarding the vendor's practices.
4. Consequently, there was a likelihood that the approval process for Unicycive's product, oxylanthanum carbonate (OLC), would face delays.
5. The investors claim that Unicycive's optimistic statements about its business and prospects were therefore materially misleading.

As the true nature of these allegations came to light, many investors experienced significant financial losses.

Why Choose Rosen Law Firm
Rosen Law Firm is recognized for its commitment to advocating strongly for investors in securities class actions. Having secured historic settlements, including the largest-ever class action against a Chinese company, they have a reputation for excellence in this complex field. Ranked first by ISS Securities Class Action Services in 2017 for the number of settlements, Rosen Law continues to demonstrate its prowess year after year. In 2019 alone, they recovered over $438 million for investors. The firm's founding partner, Laurence Rosen, has been named a leading attorney in the securities field by various legal publications.

Get Involved
To participate in the lawsuit or to inquire further about your rights as an investor, it is crucial to act promptly, especially given the deadline of November 2, 2026. Prospective class members should note that until a class is officially certified, they may choose to remain absent from proceedings or select their counsel. If you wish to take a more active role, the opportunity to become lead plaintiff is available, facilitating direct involvement in guiding the litigation.

Stay Updated
For ongoing updates, investors can follow the firm on professional social media platforms like LinkedIn, Twitter, or Facebook.

Final Note
As always, prospective participants should ensure they engage qualified legal counsel experienced in securities litigation. Choosing the right representation can greatly impact the outcome of any class action lawsuits and provide the best chances for recovery.